Mabeya S, Nyamache A, Ngugi C, Nyerere A, Lihana R
Ethiop J Health Sci. 2020; 30(1):37-44.
PMID: 32116431
PMC: 7036466.
DOI: 10.4314/ejhs.v30i1.6.
Soret P, Avalos M, Wittkop L, Commenges D, Thiebaut R
BMC Med Res Methodol. 2018; 18(1):159.
PMID: 30514234
PMC: 6280495.
DOI: 10.1186/s12874-018-0609-4.
Sepulveda-Torres L, Rishishwar L, Rogers M, Rios-Olivares E, Boukli N, Jordan I
PLoS One. 2017; 12(5):e0177452.
PMID: 28493944
PMC: 5426751.
DOI: 10.1371/journal.pone.0177452.
Zeh C, Inzaule S, Ondoa P, Nafisa L, Kasembeli A, Otieno F
PLoS One. 2016; 11(2):e0147436.
PMID: 26871567
PMC: 4752262.
DOI: 10.1371/journal.pone.0147436.
Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L
J Acquir Immune Defic Syndr. 2015; 70(1):42-53.
PMID: 26322666
PMC: 4556171.
DOI: 10.1097/QAI.0000000000000671.
The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.
Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q
AIDS Res Ther. 2015; 11:36.
PMID: 25926857
PMC: 4414387.
DOI: 10.1186/1742-6405-11-36.
Molecular mechanisms and design principles for promiscuous inhibitors to avoid drug resistance: lessons learned from HIV-1 protease inhibition.
Shen Y, Radhakrishnan M, Tidor B
Proteins. 2014; 83(2):351-72.
PMID: 25410041
PMC: 4829108.
DOI: 10.1002/prot.24730.
Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug.
Jayaswal A, Mishra A, Mishra H, Shah K
Bioinformation. 2014; 10(4):227-32.
PMID: 24966525
PMC: 4070054.
DOI: 10.6026/97320630010227.
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.
Hohlfeld K, Tomassi C, Wegner J, Kesteleyn B, Linclau B
ACS Med Chem Lett. 2014; 2(6):461-5.
PMID: 24900331
PMC: 4018169.
DOI: 10.1021/ml2000356.
The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysis.
Sargeant D, Deverasetty S, Strong C, Alaniz I, Bartlett A, Brandon N
PLoS One. 2014; 9(6):e98810.
PMID: 24886930
PMC: 4041786.
DOI: 10.1371/journal.pone.0098810.
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A
AIDS Patient Care STDS. 2014; 28(4):168-75.
PMID: 24660840
PMC: 3985528.
DOI: 10.1089/apc.2013.0310.
Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010).
Carter A, Min J, Chau W, Lima V, Kestler M, Pick N
PLoS One. 2014; 9(3):e92334.
PMID: 24642949
PMC: 3958538.
DOI: 10.1371/journal.pone.0092334.
How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?.
Braithwaite R, Nucifora K, Toohey C, Kessler J, Uhler L, Mentor S
AIDS. 2014; 28 Suppl 1:S73-83.
PMID: 24468949
PMC: 4089870.
DOI: 10.1097/QAD.0000000000000110.
Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study.
Ribeiro K, Biscione F, Westin M, Machado D, Greco D, Tupinambas U
Braz J Infect Dis. 2013; 18(1):1-7.
PMID: 23916454
PMC: 9425192.
DOI: 10.1016/j.bjid.2013.04.001.
Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005.
Cubano L, Cumba L, del Sepulveda-Torres L, Boukli N, Rios-Olivares E
Bol Asoc Med P R. 2013; 102(3):13-7.
PMID: 23875516
PMC: 4556367.
Directly administered antiretroviral therapy for HIV-infected individuals in opioid treatment programs: results from a randomized clinical trial.
Lucas G, Mullen B, Galai N, Moore R, Cook K, McCaul M
PLoS One. 2013; 8(7):e68286.
PMID: 23874575
PMC: 3712961.
DOI: 10.1371/journal.pone.0068286.
Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.
Land S, Zhou J, Cunningham P, Sohn A, Singtoroj T, Katzenstein D
J Int AIDS Soc. 2013; 16:18580.
PMID: 23845227
PMC: 3709369.
DOI: 10.7448/IAS.16.1.18580.
Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine.
Siripassorn K, Manosuthi W, Pakdee A, Natprom S, Chaovavanich A, Hengphadpanadamrong N
AIDS Res Ther. 2013; 10(1):4.
PMID: 23347647
PMC: 3576311.
DOI: 10.1186/1742-6405-10-4.
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.
Foulkes-Murzycki J, Rosi C, Yilmaz N, Shafer R, Schiffer C
ACS Chem Biol. 2012; 8(3):513-8.
PMID: 23252515
PMC: 3805267.
DOI: 10.1021/cb3006193.
Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth.
Wong F, Hsu A, Pham P, Siberry G, Hutton N, Agwu A
Pediatr Infect Dis J. 2012; 31(12):1279-83.
PMID: 22926213
PMC: 3745639.
DOI: 10.1097/INF.0b013e31826fd3e7.
